Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 8/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.37 |
| ▸ | USP1 | O94782 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 3/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30983906 | 0.92 | PIK3CD (0.39) | PDE10APIK3CDCNR1CNR2 | |
| SCHEMBL30984005 | 0.91 | CFTR (0.40) | PDE10APIK3CDYTHDC1CNR1CNR2 | |
| SCHEMBL31321972 | 0.90 | PIK3CD (0.38) | PDE10APIK3CDCNR1CNR2 | |
| SCHEMBL30983480 | 0.89 | F2 (0.39) | PDE10APIK3CDUSP1CNR1BRD4 | |
| SCHEMBL31269478 | 0.88 | SYK (0.36) | SCN9APIK3CDESR2MAPK10 | |
| SCHEMBL30983512 | 0.87 | KMT2A (0.36) | PIK3CDCNR1CNR2 | |
| SCHEMBL31268855 | 0.86 | CNR1 (0.38) | PIK3CDCNR1 | |
| SCHEMBL30983776 | 0.86 | PIK3CD (0.40) | PDE10APIK3CDCNR1CNR2 | |
| SCHEMBL30983826 | 0.85 | PIK3CD (0.39) | PDE10APIK3CDCNR1CNR2 | |
| SCHEMBL30983954 | 0.85 | PLA2G2A (0.39) | PIK3CDCNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12414954-B2 | POLQ inhibitors | ASTRAZENECA AB (SE) | 2025-09-16 | — | — | US | disclosed |
| US-20250195530-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2025-06-19 | — | — | US | disclosed |
| US-20240366615-A1 | POLQ INHIBITORS | ASTRAZENECA UK LIMITED (GB) | 2024-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366615-A1 | POLQ INHIBITORS | POLQ, POLG, POLB | MAPK14 3170/4885SCN9A 1200/4885PDE10A 1995/4885 |
| US-12414954-B2 | POLQ inhibitors | POLQ, POLG, POLB | MAPK14 3170/4885SCN9A 1200/4885PDE10A 1995/4885 |
| US-20250195530-A1 | POLQ INHIBITORS | POLQ, POLG, POLB | MAPK14 3170/4885SCN9A 1200/4885PDE10A 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.